| |
| Xpention
Genetics, Inc. is
a biotechnology company that was formed to develop both immunological
and molecular tests for cancer detection in animals and humans
as well as therapeutic vaccines and other treatment methods
for both veterinary and human cancers. Xpention through its
subsidiary has licensed, exclusive rights to a specific genetic
marker called the p65 that has highly specific correlation
to numerous cancers. |
| |
 |
|
|
|
|
| |
| |
|
|
| |
|
|
| |
|
Studies |
| |
|
|
|
|
P65 is a promising marker for the early
detection of malignant tumor formation and a useful tool for monitoring
therapy and remission. Levels of p65 also appear to have a
direct correlation to tumor mass.
In an initial study performed, 67 dogs with lymphosarcoma and
14 normal dogs were evaluated for p65 levels with the following
findings:
Sensitivity: 0.94
Specificity: 0.70
Predictive Value: 0.83
(elevated p65 & presence
of cancer) |
|
